The genetic spectrum of LRRK2 variants in Parkinson's disease: findings from a large Chinese cohort.
Sequencing of LRRK2 in 20,519 Chinese individuals reveals enrichment of known pathogenic/likely pathogenic variants in PD, identifies novel candidate pathogenic variants (e.g., p.A312V, p.M968K, p.R1320S), and confirms common PD-associated alleles (p.A419V, p.R1628P, p.G2385R) with no similar…
What the AI sees
Sequencing of LRRK2 in 20,519 Chinese individuals reveals enrichment of known pathogenic/likely pathogenic variants in PD, identifies novel candidate pathogenic variants (e.g., p.A312V, p.M968K, p.R1320S), and confirms common PD-associated alleles (p.A419V, p.R1628P, p.G2385R) with no similar…
Research significance
This large-population genetic map of LRRK2 enables patient stratification and clinical-trial enrichment for LRRK2-targeted therapies, prioritizes novel variants for functional follow-up, and supports development of genotype-guided biomarkers and personalized PD interventions.
Source abstract
The pathogenicity of variants of uncertain significance in the LRRK2 gene remains underexplored. Investigating the LRRK2 variant spectrum in a large Chinese population cohort can provide deeper insights into its pathogenic mechanisms. This study examined the LRRK2 gene variants in 20,519 Chinese individuals, including 7,562 Parkinson's disease (PD) patients, 3,077 Essential tremor (ET) patients, and 9880 healthy controls. We conducted a genetic analysis of low-frequency and common non-synonymous variants in the LRRK2 gene across the cohorts. A total of 287 low-frequency non-synonymous LRRK2 variants were identified in the PD and control cohorts. Among these, six reported pathogenic variants (p.R1325Q, p.R1441C, p.R1441H, p.V1447M, p.G2019S, p.I2020T) and three reported likely pathogenic variants (p.R1067Q, p.N1437D, p.R1728H) were enriched in PD cases, with a frequency of 0.71%. In contrast, only one pathogenic variant (p.R1325Q) and one likely pathogenic variant (p.R1067Q) were observed in healthy controls (0.11%), and the ET cohort exhibited similar variant distribution to controls (0.19%). Burden analysis and association analysis revealed novel likely pathogenic variants, including p.A312V, p.M968K, and p.R1320S as candidates. These novel variants were significantly more frequent in PD patients (0.79%) compared to healthy controls (0.20%) or ET patients (0.42%). Additionally, seven common missense variants of LRRK2 were identified, and significant associations with PD for p.A419V, p.R1628P, and p.G2385R were confirmed, but no common variants were linked to ET. This study provides the first comprehensive characterization of the LRRK2 variant spectrum in a large Chinese population, underscoring the pivotal role of LRRK2 in PD pathogenesis but not in ET. These findings advance the understanding of LRRK2 in neurodegenerative disorders and lay a foundation for personalized therapeutic strategies based on genetic profiling.